Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Università del Piemonte Orientale Home
Italiano
English
Home
Profili
Unità di ricerca
Apparecchiatura
Progetti
Risultato della ricerca
Ricerca per competenza, nome o affiliazione
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
Alberto Papi
, Michael G. Ison
, Joanne M. Langley
, Dong Gun Lee
, Isabel Leroux-Roels
, Federico Martinon-Torres
, Tino F. Schwarz
, Richard N. Van Zyl-Smit
, Laura Campora
, Nancy Dezutter
, Nathalie De Schrevel
, Laurence Fissette
, Marie Pierre David
, Marie Van Der Wielen
, Lusine Kostanyan
, Veronica Hulstrøm
Risultato della ricerca
:
Contributo su rivista
›
Articolo in rivista
›
peer review
Panoramica
Fingerprint
Fingerprint
Entra nei temi di ricerca di 'Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults'. Insieme formano una fingerprint unica.
Ordina per
Peso
Alfabetico
Keyphrases
Acceptable Safety
5%
Acute Respiratory Infection
27%
Adjuvanted
5%
Adverse Events
5%
Age Groups
5%
B Subtype
5%
Clinical Complications
5%
Clinical Death
5%
Clinical Signs
5%
Coexisting Conditions
11%
Confidence Interval
22%
F Protein
100%
Lower Limit
5%
Lower Respiratory Tract Infection
44%
Mandatory Vaccines
5%
Moderate Severity
5%
Moderate to Severe
5%
Older Adults
100%
One Dose
11%
Phase II Trial
5%
Placebo
16%
Placebo Groups
5%
Placebo-controlled
5%
Potential Immune-mediated Diseases
5%
Prefusion F
100%
Protein Vaccine
100%
Protein-based
5%
Quantitative PCR
11%
Respiratory Syncytial Virus
100%
Respiratory Syncytial Virus Infection
5%
Safety Profile
5%
Serious Adverse Events
5%
Vaccine Antigen
5%
Vaccine Effectiveness
27%
Virus Subtypes
11%
Medicine and Dentistry
Adverse Event
11%
Diseases
5%
Human Respiratory Syncytial Virus
100%
Human Respiratory Syncytial Virus A
5%
Lower Respiratory Tract
47%
Placebo
29%
Respiratory Disease
47%
Respiratory Syncytial Virus Infection
5%
Respiratory Tract Infection
29%
Reverse Transcription Polymerase Chain Reaction
11%
Single Drug Dose
11%
Vaccine Efficacy
29%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Diseases
5%
Human Respiratory Syncytial Virus
100%
Human Respiratory Syncytial Virus A
5%
Placebo
29%
Respiratory Syncytial Virus Infection
5%
Respiratory Tract Disease
47%
Respiratory Tract Infection
29%
RNA Directed DNA Polymerase
11%
Vaccine Efficacy
29%
Immunology and Microbiology
Human Respiratory Syncytial Virus
100%
Human Respiratory Syncytial Virus A
5%
Lower Respiratory Tract
47%
Respiratory Syncytial Virus Infection
5%
Reverse Transcription Polymerase Chain Reaction
11%
Vaccine Efficacy
29%
Biochemistry, Genetics and Molecular Biology
Human Respiratory Syncytial Virus
100%
Human Respiratory Syncytial Virus A
5%
Reverse Transcription Polymerase Chain Reaction
11%
Single Drug Dose
11%